Study record
MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases
Amado CA, Agüero J, García-Unzueta M et al. · J Transl Med · 2026
What this study reported
Reviewed evidence that circulating MOTS-c is reported lower in acute respiratory distress and in chronic obstructive pulmonary disease, obstructive sleep apnea and asthma, and higher in lung cancer in preliminary observations. Summarised preclinical reports that administered MOTS-c attenuated lung injury and that remote ischemic preconditioning may act partly through MOTS-c release.
Limitations
Narrative review without systematic search or risk-of-bias assessment; the underlying clinical data are small and heterogeneous, and the authors note that validation is lacking.
Study record
| Study model | Review |
|---|---|
| Substance studied | SeveralMore than one of these is central to the paper (common for reviews). |
| Species | Not reported |
| System studied | Narrative review of MOTS-c in acute and chronic inflammatory lung disease |
| Population | Not reported |
| Design | Narrative review |
| Sample size as reported | Not reported |
| Control group | Not reported |
| Route (data field only) | Not reported |
| Endpoints measured | circulating MOTS-c levels across respiratory conditions; preclinical lung injury outcomes; proposed mechanisms |
| Pathways measured | Inflammation · Oxidative stress · Autophagy / mitophagy · Apoptosis |
| Research areas | Lung · Inflammation & immunity · Mitochondrial biology |
| Evidence tier | R — Review (context, not evidence) |
| Publication types | Journal Article, Review |
Appraisal
Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.
- Relevance to MOTS-c
- Direct
- Model applicability
- n/a
- Sample size
- n/a
- Controls
- n/a
- Outcome validity
- n/a
- Support for its own conclusion
- n/a
Provenance
- Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
- Annotated from the published abstract.
- Editorial review: approved (2026-11-11).
- Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.